We are growing our operational team! 💪 We have a position advertised for a Science Operations Manager on our website at the moment. Share with others you think may be suitable! Position closing soon... ⏱️
Cyclana Bio
Biotechnology Research
A tissue-level multidisciplinary approach to curing Endometriosis.
About us
Our mission is to cure endometriosis. We are a team of interdisciplinary scientists creating a new model in women's health research centred around an in depth understanding of tissue-level disease processes. We are committed to improving the quality of life of women by providing a new model for therapeutic discovery. We sit at the interface between tissue biology, computation and laboratory disease modelling.
- Website
-
https://www.cycletherapeutics.org
External link for Cyclana Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cambridge
- Type
- Privately Held
Locations
-
Primary
Get directions
Cambridge, GB
Employees at Cyclana Bio
Updates
-
And just like that our team has grown again! We are absolutely thrilled to welcome two incredible scientists within our ranks to help translate our insights into tangible solutions for women with endometriosis. Helen Harrison has joined us as our Director of Discovery and Translational Biology. Her years of experience across modalities and indications make her the perfect person to help us revolutionise the therapeutic field of women's health! Andrew Miller, PhD has joined us as a Founding Scientist, at the interface of computational and experimental biology. His deep stromal and mechanobiology expertise have gotten him diving right into the lab already. Welcome to our mission both, let the breakthroughs continue!
-
-
#21toWatch - We were delighted and honoured to be recognised as one of seven companies in East of England driving forward much needed change (along with our great Babraham Research Campus neighbour Kourosh Sam Kamali)! What started off as a desire to shine a light on women's health, has grown so quickly into a larger but just as driven and passionate team, working daily on the basic biology that drives diseases like endometriosis. Thanks to our CSO Kevin Chalut for delivering a perfect 60s pitch, to the sponsors, judges and partners of this great event and to Innovate Cambridge for welcoming us at the Glasshouse. So you heard it from Faye Holland first, watch this space... 👀
-
-
We're thrilled to announce that Jonathan Griffiths has joined Cyclana Bio as Chief Technology Officer (CTO), where he'll be leading our computational efforts to advance women's health research. Jonny brings an unusually interdisciplinary background, with deep expertise spanning biology, functional genomics, human genetics, and machine learning—skills he combines to solve complex problems at their intersection. Previously, Jonny led machine learning teams at Altos Labs developing large language models for epigenetics, identified novel therapeutic targets for SLE at Genomics plc, and pioneered early analyses of large-scale single-cell RNA-sequencing data during his PhD in John Marioni's lab at the CRUK Cambridge Institute. We're excited to have Jonny's expertise as we work to transform our understanding of endometriosis and related conditions through innovative biomarker discovery. Welcome to the team, Jonny! 🥼 💻
-
-
Celebrating this year's science and the foundations that we have laid, for next year to bring us even closer to groundbreaking therapies in women's health. And with that, we are welcoming Siiri Salomaa to our ranks as a Founding Scientist! This title reflects how central of a role the team we are building today has in driving our mission forward. We're so excited to have you on board Siiri and to benefit from your wealth of experience in the field of mechanobiology. Wishing all of those who are following our journey Happy Holidays and a great 2026 from the Cyclana Team (filled with many more uterus-shaped gingerbread biscuits, courtesy of Louise Shanahan...).
-
-
Staying embedded within the academic sphere and discovery science is someone we believe in strongly and it’s always great to have our CSO and Co-Founder Kevin engage with the academic community!
I had a great time at the Laboratory for Medical Sciences at Imperial College earlier this week, doing one of my favourite things - talking about ECM and its essential role in building and maintaining tissue. I don't know how many times I have given such seminars or talks as an academic, sharing with people why I think ECM and tissue repair are such exciting, inextricably linked topics. But in this case, it was an especially interesting day, because it was the same day that we announced our raise at Cyclana Bio. This made it very real to me, really hit me that for right now (and who knows about the future) I am thinking about that science differently, and maybe even less as an academic. So here we are, Léa Wenger and I have been talking for a while about how there's a really important vector towards new targets, particularly for women's health, centred on matrix and tissue biology. Endometriosis, which has personal meaning for both of us, is our indication of choice. We are going to be sharing some papers and other developments here as we go. I will never lose my faith in the power of the discovery-based science I have grown up with - it is the engine of innovation. This hit home even further at Imperial, with such great discussions with amazing scientists around cell and tissue biology. I truly believe it's possible to work within the discovery and innovation mindset to bring new therapies to market that will revolutionise human health.
-
-
We're pleased to announce that we've closed £5 million funding to support the development of our whole tissue-based platform and scaling of our observational clinical trial for endometriosis. The investment—co-led by NFX and Eka Ventures with support from Cocoa 🍫, Wilbe, and Angel investors—reinforces the potential of our physiologically relevant models and AI-driven multi-scale data integration approach to enable for the development of effective treatments for endometriosis. It will support our mission to accelerate the development of a cure for this debilitating disease, which affects one in ten women worldwide. Read the full press release here: https://lnkd.in/esm9wbvK #WomensHealth #Endometriosis
-
-
Help us get the best data in women's health! 🧑🔬 🔬 🧪 We are currently looking for feedback on our latest observational clinical study. We are collecting tissue biopsies from women that are undergoing an intervention that would allow for risk free collection (timed for example with a surgery). This includes people with endometriosis as well as people that do not have the disease. We use this data to develop better disease models and better predict disease outcomes in patients. Why do we want feedback? We want to ensure that the information we provide is accessible and that we clearly communicate what is involved. This is also a chance for you to suggest how we could make our study better (feel free to drop some suggestions in the comments too!). How can you help? If you could be or have been in a situation to be eligible for our study (a women that could undergo a procedure, most often related to gynaecology), please in your own time take a look at our documents and give us some feedback here: https://lnkd.in/eneRPA7J. What do you get? This feedback is anonymous, so won't benefit you directly. However, you will be contributing to the improvement of research in women's health and to developing better treatments for the future! If you want to engage with us further, drop us a message in the comments or message us directly. Let's get this solved together!
-
Cyclana Bio reposted this
Yesterday all afternoon, Kevin Chalut and I had our first formal company deep dive. We’ve been busy with fundraising, conferences, operations and haven’t had much time outside of lab meeting to truly sit down and discuss our scientific direction, our key assumptions and research priorities. Yesterday our agenda consisted of three main themes: 1) The science - always the starting point. How do we build a cure for a disease we don’t yet understand? What key assumptions are safe to hold true? What does success look like? 2) The business - how can we work within a larger ecosystem? How can we make partnerships generate the greatest value for women’s health whilst retaining our commercial potential? 3) The culture - what culture do we want to promote? How does that fit in with both or our personalities and leadership styles. But most importantly, it focussed on an honest discussion of how the two of us had been working together so far: what were our concerns? Our fears? What worked? That last discussion was the best part of the afternoon! I was shocked that we somehow managed to cover almost all of the questions we had prepared, could this be progress? 😅 Thanks to Prof. Ewa Paluch and Trinity College for hosting us. Doing this in a new setting with no distractions definitely helps you focus (and sunny views of the courts of Trinity aren't a bad bonus 😏 ). Cyclana Bio (ex. Cycle Therapeutics) #womenshealth #biotech #Cambridge #scienceinprogress
-
-
A busy week for our co-founders! Léa Wenger will be showcasing some of our latest results tomorrow in Oxford at the #WomeninBiotech event. Kevin Chalut will be giving a talk at The University of Manchester’s Manchester Cell-Matrix Centre Thursday, sharing insights will fellow researchers and collaborators. Come and say hi if you’re there!
Join us on 1 October at the Oxford University Museum of Natural History for the return of the #WomeninBiotech Innovation Showcase. ➡️ https://lnkd.in/evAKPYWN 📌 Sayoni Das, SVP of Bioinformatics, PrecisionLife 📌 Stasa Stankovic, Co-founder and CEO, OvartiX 📌 Léa Wenger, CEO and Founder, Cycle Therapeutics Join us for great networking and a critical and timely discussion.